Abstract
The nicotinic acetylcholine receptors (nAChRs) are ion channels distribute in the central or peripheral nervous system. They are receptors of the neurotransmitter acetylcholine and activation of them by agonists mediates synaptic transmission in the neuron and muscle contraction in the neuromuscular junction. Current studies reveal relationship between the nAChRs and the learning and memory as well as cognation deficit in various neurological disorders such as Alzheimer’s disease, Parkinson’s disease, schizophrenia and drug addiction. There are various subtypes in the nAChR family and the α7 nAChR is one of the most abundant subtypes in the brain. The α7 nAChR is significantly reduced in the patients of Alzheimer’s disease and is believed to interact with the Aβ amyloid. Aβ amyloid is co-localized with α7 nAChR in the senile plaque and interaction between them induces neuron apoptosis and reduction of the α7 nAChR expression. Treatment with α7 agonist in vivo shows its neuron protective and procognation properties and significantly improves the learning and memory ability of the animal models. Therefore, the α7 nAChR agonists are excellent drug candidates for Alzheimer’s disease and we summarized here the current agonists that have selectivity of the α7 nAChR over the other nAChR, introduced recent molecular modeling works trying to explain the molecular mechanism of their selectivity and described the design of novel allosteric modulators in our lab.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Graham AJ, Ray MA, Perry EK, Jaros E, Perry RH, Volsen SG, Bose S, Evans N, Lindstrom J (2003) Differential nicotinic acetylcholine receptor subunit expression in the human hippocampus. J Chem Neuroanat 25(2):97–113
Lloyd GK, Williams M (2000) Neuronal nicotinic acetylcholine receptors as novel drug targets. J Pharmacol Exp Ther 292(2):461
Nashmi R, Dickinson ME, McKinney S, Jareb M, Labarca C, Fraser SE, Lester HA (2003) Assembly of α4β2 nicotinic acetylcholine receptors assessed with functional fluorescently labeled subunits: effects of localization, trafficking, and nicotine-induced upregulation in clonal mammalian cells and in cultured midbrain neurons. J Neurosci 23(37):11554–11567
Dani JA, Bertrand D (2007) Nicotinic acetylcholine receptors and nicotinic cholinergic mechanisms of the central nervous system. Annu Rev Pharmacol Toxicol 47:699–729
Albuquerque EX, Pereira EFR, Alkondon M, Rogers SW (2009) Mammalian nicotinic acetylcholine receptors: from structure to function. Physiol Rev 89(1):73–120
Wevers A, Monteggia L, Nowacki S, Bloch W, Schütz U, Lindstrom J, Pereira EFR, Eisenberg H, Giacobini E, De Vos RAI (1999) Expression of nicotinic acetylcholine receptor subunits in the cerebral cortex in Alzheimer’s disease: histotopographical correlation with amyloid plaques and hyperphosphorylated-tau protein. Eur J Neurosci 11(7):2551–2565
Guan ZZ, Zhang X, Ravid R, Nordberg A (2000) Decreased protein levels of nicotinic receptor subunits in the hippocampus and temporal cortex of patients with Alzheimer expression of nicotinic acetylcholine receptor subunits in the cerebral cortex in Alzheimer’s disease. J Neurochem 74(1):237–243
Wevers A, Witter B, Moser N, Burghaus L, Banerjee C, Steinlein OK, Schütz U, De Vos RAI, Jansen Steur ENH, Lindstrom J (2000) Classical Alzheimer features and cholinergic dysfunction: towards a unifying hypothesis? Acta Neurol Scand 102:42–48
Luheshi LM, Tartaglia GG, Brorsson AC, Pawar AP, Watson IE, Chiti F, Vendruscolo M, Lomas DA, Dobson CM, Crowther DC (2007) Systematic in vivo analysis of the intrinsic determinants of amyloid β pathogenicity. PLoS Biol 5(11):e290
Roychaudhuri R, Yang M, Hoshi MM, Teplow DB (2009) Amyloid β-protein assembly and Alzheimer disease. J Biol Chem 284(8):4749
Oneill MJ, Murray TK, Lakics V, Visanji NP, Duty S (2002) The role of neuronal nicotinic acetylcholine receptors in acute and chronic neurodegeneration. Curr Drug Targets CNS Neurol Disord 1 (4):399–411
Grassi F, Palma E, Tonini R, Amici M, Ballivet M, Eusebi F (2003) Amyloid β1-42 peptide alters the gating of human and mouse α-bungarotoxin-sensitive nicotinic receptors. J Physiol 547(1):147–157
Dineley KT, Bell KA, Bui D, Sweatt JD (2002) β-Amyloid peptide activates α7 nicotinic acetylcholine receptors expressed in Xenopus oocytes. J Biol Chem 277(28):25056–25061
Dougherty JJ, Wu J, Nichols RA (2003) β-Amyloid regulation of presynaptic nicotinic receptors in rat hippocampus and neocortex. J Neurosci 23(17):6740–6747
Wang HY, Li W, Benedetti NJ, Lee DHS (2003) α7 nicotinic acetylcholine receptors mediate β-amyloid peptide-induced tau protein phosphorylation. J Biol Chem 278(34):31547
Freir DB, Herron CE (2003) Nicotine enhances the depressive actions of Aβ1-40 on long-term potentiation in the rat hippocampal CA1 region in vivo. J Neurophysiol 89(6):2917–2922
Wildman SS, Marks J, Churchill LJ, Peppiatt CM, Horisberger JD, King BF, Unwin RJ (2005) Molecular interactions between cloned epithelial sodium channels and ATP-gated P2X receptors. FASEB J 19(5):A1177
Miyazawa A, Fujiyoshi Y, Unwin N (2003) Structure and gating mechanism of the acetylcholine receptor pore. Nature 423(6943):949–955
Karlin A (2002) Emerging structure of the nicotinic acetylcholine receptors. Nat Rev Neurosci 3(2):102–114
Arias HR (2009) Is the inhibition of nicotinic acetylcholine receptors by bupropion involved in its clinical actions? Int J Biochem Cell Biol 41(11):2098–2108
Arias HR (2000) Localization of agonist and competitive antagonist binding sites on nicotinic acetylcholine receptors. Neurochem Int 36(7):595–645
Arias HR (2010) Molecular interaction of bupropion with nicotinic acetylcholine receptors. J Pediatr Biochem 1(2):185–197
Gu RX, Zhong YQ, Wei DQ (2011) Structural basis of agonist selectivity for different nAChR subtypes: insights from crystal structures, mutation experiments and molecular simulations. Curr Pharm Des 17(17):1652–1662
Tondera JE, Olesen PH, Hansen JB, Begtrup M, Pettersson I (2001) An improved nicotinic pharmacophore and a stereoselective CoMFA-model for nicotinic agonists acting at the central nicotinic acetylcholine receptors labelled by [3H]-N-methylcarbamylcholine. J Comput Aided Mol Des 15(3):247–258
Haydar SN, Ghiron C, Bettinetti L, Bothmann H, Comery TA, Dunlop J, La Rosa S, Micco I, Pollastrini M, Quinn J (2009) SAR and biological evaluation of SEN12333/WAY-317538: novel alpha 7 nicotinic acetylcholine receptor agonist. Bioorg Med Chem 17(14):5247–5258
Ghiron C, Haydar SN, Aschmies S, Bothmann H, Castaldo C, Cocconcelli G, Comery TA, Di L, Dunlop J, Lock T (2010) Novel alpha-7 nicotinic acetylcholine receptor agonists containing a urea moiety: identification and characterization of the potent, selective, and orally efficacious agonist 1-[6-(4-Fluorophenyl) pyridin-3-yl]-3-(4-piperidin-1-ylbutyl) urea (SEN34625/WYE-103914). J Med Chem 53(11):4379–4389
Mullen G, Napier J, Balestra M, DeCory T, Hale G, Macor J, Mack R, Loch Iii J, Wu E, Kover A (2000) (-)-Spiro [1-azabicyclo [2.2. 2] octane-3, 5’-oxazolidin-2’-one], a conformationally restricted analogue of acetylcholine, is a highly selective full agonist at the α7 nicotinic acetylcholine receptor. J Med Chem 43(22):4045–4050
Kampen M, Selbach K, Schneider R, Schiegel E, Boess F, Schreiber R (2004) AR-R 17779 improves social recognition in rats by activation of nicotinic a 7 receptors. Psychopharmacology 172(4):375–383
Boess FG, De Vry J, Erb C, Flessner T, Hendrix M, Luithle J, Methfessel C, Riedl B, Schnizler K, van der Staay FJ (2007) The novel α7 nicotinic acetylcholine receptor agonist N-[(3R)-1-azabicyclo [2.2. 2] oct-3-yl]-7-[2-(methoxy) phenyl]-1-benzofuran-2-carboxamide improves working and recognition memory in rodents. J Pharmacol Exp Ther 321(2):716
Malysz J, Anderson DJ, Gr Nlien JH, Ji J, Bunnelle WH, H Kerud M, Thorin-Hagene K, Ween H, Helfrich R, Hu M (2010) In vitro pharmacological characterization of a novel selective α7 neuronal nicotinic acetylcholine receptor agonist ABT-107. J Pharmacol Exp Ther 334(3):863
Othman AA, Lenz RA, Zhang J, Li J, Awni WM, Dutta S (2011) Single-and multiple-dose pharmacokinetics, safety, and tolerability of the selective α7 neuronal nicotinic receptor agonist, ABT-107, in healthy human volunteers. J Clin Pharmacol 51(4):512
Roncarati R, Scali C, Comery TA, Grauer SM, Aschmi S, Bothmann H, Jow B, Kowal D, Gianfriddo M, Kelley C (2009) Procognitive and neuroprotective activity of a novel α7 nicotinic acetylcholine receptor agonist for treatment of neurodegenerative and cognitive disorders. J Pharmacol Exp Ther 329(2):459
Hauser TA, Kucinski A, Jordan KG, Gatto GJ, Wersinger SR, Hesse RA, Stachowiak EK, Stachowiak MK, Papke RL, Lippiello PM (2009) TC-5619: an alpha7 neuronal nicotinic receptor-selective agonist that demonstrates efficacy in animal models of the positive and negative symptoms and cognitive dysfunction of schizophrenia. Biochem Pharmacol 78(7):803–812
O’Donnell CJ, Peng L, O’Neill BT, Arnold EP, Mather RJ, Sands SB, Shrikhande A, Lebel LA, Spracklin DK, Nedza FM (2009) Synthesis and SAR studies of 1, 4-diazabicyclo [3.2. 2] nonane phenyl carbamates-subtype selective, high affinity [alpha] 7 nicotinic acetylcholine receptor agonists. Bioorg Med Chem Lett 19(16):4747–4751
Bodnar AL, Cortes-Burgos LA, Cook KK, Dinh DM, Groppi VE, Hajos M, Higdon NR, Hoffmann WE, Hurst RS, Myers JK (2005) Discovery and structure-activity relationship of quinuclidine benzamides as agonists of α7 nicotinic acetylcholine receptors. J Med Chem 48(4):905–908
Hajos M, Hurst RS, Hoffmann WE, Krause M, Wall TM, Higdon NR, Groppi VE (2005) The selective α7 nicotinic acetylcholine receptor agonist PNU-282987 [N-[(3R)-1-azabicyclo [2.2. 2] oct-3-yl]-4-chlorobenzamide hydrochloride] enhances GABAergic synaptic activity in brain slices and restores auditory gating deficits in anesthetized rats. J Pharmacol Exp Ther 312(3):1213
Acker BA, Jacobsen EJ, Rogers BN, Wishka DG, Reitz SC, Piotrowski DW, Myers JK, Wolfe ML, Groppi VE, Thornburgh BA (2008) Discovery of N-[(3R, 5R)-1-azabicyclo [3.2. 1] oct-3-yl] furo [2, 3-c] pyridine-5-carboxamide as an agonist of the [alpha] 7 nicotinic acetylcholine receptor: in vitro and in vivo activity. Bioorg Med Chem Lett 18(12):3611–3615
Briggs CA, Anderson DJ, Brioni JD, Buccafusco JJ, Buckley MJ, Campbell JE, Decker MW, Donnelly-Roberts D, Elliott RL, Gopalakrishnan M (1997) Functional characterization of the novel neuronal nicotinic acetylcholine receptor ligand GTS-21 in vitro and in vivo. Pharmacol Biochem Behav 57(1–2):231–241
Feuerbach D, Nozulak J, Lingenhoehl K, McAllister K, Hoyer D (2007) JN403, in vitro characterization of a novel nicotinic acetylcholine receptor [alpha] 7 selective agonist. Neurosci Lett 416(1):61–65
Feuerbach D, Lingenhoehl K, Olpe HR, Vassout A, Gentsch C, Chaperon F, Nozulak J, Enz A, Bilbe G, McAllister K (2009) The selective nicotinic acetylcholine receptor [alpha] 7 agonist JN403 is active in animal models of cognition, sensory gating, epilepsy and pain. Neuropharmacology 56(1):254–263
Sydserff S, Sutton EJ, Song D, Quirk MC, Maciag C, Li C, Jonak G, Gurley D, Gordon JC, Christian EP (2009) Selective [alpha] 7 nicotinic receptor activation by AZD0328 enhances cortical dopamine release and improves learning and attentional processes. Biochem Pharmacol 78(7):880–888
Castner SA, Hudzik T, Maier DL, Mrzljak L, Piser T, Smith JS, Widzowski D, Williams GV (2009) A composition comprising (R)-spiro [L-Azabicyclo [2.2. 2] Octane-3, 2’(3’H)-Furo [2, 3-B] Pyridine (AZD0328) and its use in the treatment of Alzheimer’s disease, ADHD or cognitive dysfunction. EP patent 2,120,937
Haydar SN, Dunlop J (2010) Neuronal nicotinic acetylcholine receptors-targets for the development of drugs to treat cognitive impairment associated with schizophrenia and Alzheimer’s disease. Curr Top Med Chem 10(2):144–152
Lopez-Hernandez G, Placzek AN, Thinschmidt JS, Lestage P, Trocme-Thibierge C, Morain P, Papke RL (2007) Partial agonist and neuromodulatory activity of S 24795 for alpha7 nAChR responses of hippocampal interneurons. Neuropharmacology 53(1):134–144
Wang HY, Bakshi K, Shen C, Frankfurt M, Trocmé-Thibierge C, Morain P (2010) S 24795 limits [beta]-Amyloid-[alpha] 7 nicotinic receptor interaction and reduces Alzheimer’s disease-like pathologies. Biol Psychiatry 67(6):522–530
Anderson DJ, Bunnelle W, Surber B, Du J, Surowy C, Tribollet E, Marguerat A, Bertrand D, Gopalakrishnan M (2008) [3H]A-585539[(1S,4S)-2, 2-Dimethyl-5-(6-phenylpyridazin-3-yl)-5-aza-2-azoniabicyclo [2.2. 1] heptane], a novel high-affinity α7 neuronal nicotinic receptor agonist: radioligand binding characterization to rat and human brain. J Pharmacol Exp Ther 324(1):179
Bitner RS, Bunnelle WH, Anderson DJ, Briggs CA, Buccafusco J, Curzon P, Decker MW, Frost JM, Gronlien JH, Gubbins E (2007) Broad-spectrum efficacy across cognitive domains by α7 nicotinic acetylcholine receptor agonism correlates with activation of ERK1/2 and CREB phosphorylation pathways. J Neurosci 27(39):10578
Pichat P, Bergis OE, Terranova JP, Urani A, Duarte C, Santucci V, Gueudet C, Voltz C, Steinberg R, Stemmelin J (2006) SSR180711, a novel selective α7 nicotinic receptor partial agonist: (II) efficacy in experimental models predictive of activity against cognitive symptoms of schizophrenia. Neuropsychopharmacology 32(1):17–34
Sabbagh MN (2009) Drug development for Alzheimer’s disease: where are we now and where are we headed? Am J Geriatr Pharmacother 7(3):167–185
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Shanghai Jiaotong University Press, Shanghai and Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Fan, H., Gu, R., Wei, D. (2015). The α7 nAChR Selective Agonists as Drug Candidates for Alzheimer’s Disease. In: Wei, D., Xu, Q., Zhao, T., Dai, H. (eds) Advance in Structural Bioinformatics. Advances in Experimental Medicine and Biology, vol 827. Springer, Dordrecht. https://doi.org/10.1007/978-94-017-9245-5_21
Download citation
DOI: https://doi.org/10.1007/978-94-017-9245-5_21
Published:
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-017-9244-8
Online ISBN: 978-94-017-9245-5
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)